Signs of multiple sclerosis show up in blood years before symptoms, study finds
In a discovery that could hasten treatment for patients with multiple sclerosis (MS), UC San Francisco scientists have discovered a…
High Epstein-Barr antibody levels over time may aid MS diagnosis
Study points to potential way to distinguish MS from other conditions Written by Marisa Wexler, MS | March 16, 2026 Most people with multiple…
Stuart Schlossman
Online Survey: Stress and MS – from the National MS Society
March 2026 Kenneth, diagnosed in 2014 Researchers are committed to finding solutions for everyone affected by MS. Without…
Stuart Schlossman
MS Trial Alert: Investigators Recruiting Nationwide for Study Comparing AHSCT to Other Therapies in Active Relapsing MS
Researchers are committed to finding solutions for everyone affected by MS. Without participants—like you—in research studies, MS research would come…
Stuart Schlossman
Genentech’s Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
– FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing…
Stuart Schlossman
Having parents who smoked increases risk of pediatric MS: Study
Limiting children’s exposure to cigarette smoke may reduce chances of onset Written by Marisa Wexler, MS | February 26, 2026 Having parents who…
Stuart Schlossman
How Does Alcohol Affect MS?
By Crystal Hoshaw – Published on January 23, 2026Medically Reviewed by Barbara S. Giesser, MD, FAAN, FANA, Dipl. ABLM Note:…
Stuart Schlossman
ACTRIMS 2026: Blocking C3 protein seen to ease MS severity in older mice
Complement system own to reduce disease severity in older mice Written by Lila Levinson, PhD | February 9, 2026 The complement system —…
Stuart Schlossman
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
February 7, 2026 – Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of…
Stuart Schlossman
Congress Approves Funding for MS Research Program, PBM Reforms and More
February 3, 2026 On February 3, 2026, Congress passed a bipartisan FY2026 funding package that included the following: Department of…
Stuart Schlossman
